Race in a Bottle

Drugmakers are eager to develop medicines targeted at ethnic groups, but so far they have made poor choices based on unsound science. This article focuses on the drug, BiDil – a drug that combats congestive heart failure by dilating the arteries and veins of African American patients. The author expounds that there is no solid evidence that the drug should targeted towards only one ethnic group. The author includes the history of BiDil including its inception and then its reappearance with a race-based focus